medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (3)

Molecular targeted therapies: current perspectives in acute promyelocytic leukemia

Barroso SG, Hernández PC

Language: Spanish
References: 20
Page: 1-11
PDF size: 248.63 Kb.


ABSTRACT

Introduction: Acute promyelocytic leukemia is a biologically and clinically different type from other acute myeloid leukemias. The discovery of molecular details in its pathogenesis enabled its treatment to constitute one of the best examples of translational research and makes a model for the development of targeted therapies with a curative approach in cancer patients. Objective: To analize the main advances in PML therapy from the discovery of differentiating agents to their current state. Methods: An exhaustive search was carried out in the databases as Scielo, Pubmed, ScienceDirect, Redalyc, and updated articles published mainly in the last five years were used as references. Analysis and synthesis of the information: The article addressed the main advances in the therapy of this type of leukemia, from the discovery of differentiating agents to its current state, emphasizing its mechanism of action and new therapeutic options. Conclusions: The contributions made in the etiopathogenic and molecular study of promyelocytic leukemia and its objective impact on clinical research constitute one of the best examples of treatment aimed at specific molecular alterations and represents a model of biological, clinical and therapeutic integration in benefit of patients affected with this disease.


REFERENCES

  1. Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget. 2020;11(11):992-1003. DOI: https://10.18632/oncotarget.27513

  2. Xavier Thomas Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia Oncol Ther.2019;7:33-65 DOI: https://doi.org/10.1007/s40487-018-0091-5

  3. Ng CH, Chng WJ. Recent advances in acute promyelocytic leukaemia. F1000Res. 2017;6:1273. DOI: https://10.12688/f1000research.10736.1

  4. Ryan MM. Acute Promyelocytic Leukemia: A Summary. J Adv Pract Oncol. 2018 Mar;9(2):178-87

  5. de Thé H, Pandolfi PP, Chen Z. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer cell. 2017;32(5):552-60. DOI: https://doi.org/10.1016/j.ccell.2017.10.002

  6. Hillestad LK. Acute Promyelocytc Leukemia. Acta Med Scan. 1957;159(3):189-94.

  7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the Classification of the Acute Leukaemias. Br J Haematology. 1976;33:451-8.

  8. Cingam SR, Koshy NV. AcutePromyelocyticLeukemia (APL, APML). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.

  9. Walasek A. The new perspectives of targeted therapy in acute myeloid leukemia. Adv Clin Exp Med. 2019;28(2):271-6. DOI: https://10.17219/acem/81610

  10. Hernández Padrón C. Tratamiento de la leucemia promielocítica con trióxido de arsénico y acidotrans-retinoico. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2017 [acceso 24/10/2018];33(1):1-13. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892017000100008&nrm=iso.

  11. Noguera NI, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, et al. Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. Cancers (Basel). 2019 Oct 18;11(10):1591. DOI: https://10.3390/cancers11101591

  12. Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute Promyelocytic Leukemia: A Constellation of Molecular Eventsaround a Single PML-RARA Fusion Gene. Cancers (Basel). 2020;12(3):624. DOI: https://10.3390/cancers12030624

  13. McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther. 2017;10:1585-601.

  14. Gurnari C, De Bellis E, Divona M, Ottone T, Lavorgna S, Voso MT. When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. Chemotherapy. 2019;64(5-6):238-47. DOI: https://10.1159/000507805

  15. Zhang P. On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia. Leuk Res Rep. 2017;7:29-32. DOI: https:// DOI: https://10.1016/j.lrr.2017.03.001

  16. Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016;122(8):1160-8. DOI: https://10.1002/cncr.29852

  17. Khairul I, Wang QQ, Jiang YH, Wang C, Naranmandura H. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 2017;8(14):23905-26. DOI: https://10.18632/oncotarget.14733

  18. Ramaekers BLT, Riemsma R, Grimm S. Arsenic Trioxide for Treating Acute PromyelocyticLeukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019;37(7):887-94. DOI: https://10.1007/s40273-018-0738-y

  19. Sanz MA, Fenaux P, Tallman MS. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European Leukemia Net. Blood. 2019;133(15):1630-43. DOI: https://10.1182/blood-2019-01-894980

  20. Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. Synergistic targeted therapy for acute promyelocyticleukaemia: a model of translational research in human cancer. J Intern Med. 2015;278(6):627-42. DOI: https://10.1111/joim.12376




2020     |     www.medigraphic.com